© Copyright 2008 by the Society for Neuro-Oncology
Received July 12, 2007
Accepted October 24, 2007
Basic and Translational Investigations
|
The methylenetetrahydrofolate reductase (MTHFR) variant c.677C>T (A222V) influences overall survival of patients with glioblastoma multiforme
Michael Linnebank 1*,
Alexander Semmler 1,
Susanna Moskau 1,
Yvo Smulders 2,
Henk Blom 2,
Matthias Simon 3
1 University Hospital Bonn, Department of Neurology, Bonn, Germany
2 VU University Hospital Amsterdam, Department of Internal Medicine and Metabolic Unit, Amsterdam, The Netherlands
3 University Hospital Bonn, Department of Neurosurgery, Bonn, Germany
* To whom correspondence should be addressed. E-mail: michael.linnebank{at}usz.ch.
 |
Abstract |
|---|
Glioblastoma multiforme (GBM) is the most frequent primary brain tumor in adults. Prognosis is poor. Using a series of 214 GBM patients, we observed an effect of the variant 5,10-methylenetetrahydrofolate reductase (MTHFR) c.677C>T on overall survival. This effect was strongest in patients younger than 60 years at diagnosis (overall survival, median ± SE: genotype CC, 13 ± 1 months; CT, 11 ± 2 months; TT, 7 ± 3 months; multivariate Cox regression analysis, Wald = 8.58, p = 0.007). In addition, the MTHFR genotype significantly influenced the overall survival of patients with a postoperative Karnofsky score >70 (CC, 12 ± 2 months; CT, 11 6 1 months; TT, 10 ± 4 months; Wald = 5.89, p = 0.015). These data suggest the MTHFR c.677C>T variant is a risk factor for survival in GBM patients.
Key Words:
glioblastoma, glioma, homocysteine, MTHFR, survival
CiteULike 
Connotea 
Del.icio.us 
Digg 
Reddit 
Technorati What's this?
